Yijin Ding

Title: Yijin Ding: Innovator in Biopharmaceuticals

Introduction

Yijin Ding is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies targeting cancer.

Latest Patents

Yijin Ding holds 2 patents that showcase his expertise in creating advanced therapeutic solutions. His latest patents include "Anti-BCMA single domain antibodies and application thereof," which describes a group of anti-BCMA single domain antibodies, their genes, and various applications in detection and treatment. These antibodies are noted for their high activity, stability, specificity, and binding capability. Another significant patent is "BCMA chimeric antigen receptor based on single domain antibody and use thereof," which details a chimeric antigen receptor (CAR) that includes a BCMA binding domain and various functional domains essential for T cell modification.

Career Highlights

Yijin Ding is currently associated with Shenzhen Pregene Biopharma Co. Ltd., where he continues to push the boundaries of biopharmaceutical research. His work focuses on developing innovative therapies that can significantly improve patient outcomes in cancer treatment.

Collaborations

Yijin collaborates with talented professionals in his field, including Jishuai Zhang and Hongjian Li, who contribute to the advancement of their shared research goals.

Conclusion

Yijin Ding's innovative work in biopharmaceuticals, particularly in the development of anti-BCMA therapies, positions him as a key figure in the fight against cancer. His contributions are paving the way for future advancements in targeted therapies.